BIO-FD&C CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,800 KRW | +6.04% |
|
+11.27% | +11.90% |
| 2023 | Tranche Update on BIO-FD&C Co.,Ltd.'s Equity Buyback Plan announced on October 19, 2022. | CI |
| 2023 | Tranche Update on BIO-FD&C Co.,Ltd.'s Equity Buyback Plan announced on October 19, 2022. | CI |
| Sales 2022 | 15.86B 11.38M | Sales 2023 | 15.59B 11.2M | Capitalization | 123B 88.16M |
|---|---|---|---|---|---|
| Net income 2022 | 4.34B 3.11M | Net income 2023 | 5.58B 4.01M | EV / Sales 2022 | 6.99 x |
| Net cash position 2022 | 36.93B 26.51M | Net cash position 2023 | 39.66B 28.48M | EV / Sales 2023 | 5.33 x |
| P/E ratio 2022 |
34.5
x | P/E ratio 2023 |
21.6
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.32% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.04% | ||
| 1 week | +11.27% | ||
| Current month | +12.06% | ||
| 1 month | +6.54% | ||
| 3 months | +22.29% | ||
| 6 months | +11.27% | ||
| Current year | +11.90% |
1 week
14 100.00
15 990.00
1 month
13 680.0015 990.00
Current year
12 090.0015 990.00
1 year
11 200.0017 300.00
3 years
11 200.0029 250.00
5 years
11 200.0029 250.00
10 years
11 200.0029 250.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dae-Hyeon Jeong
CEO | Chief Executive Officer | 52 | 04-12-31 |
Sang-Hyeon Mo
CEO | Chief Executive Officer | 48 | 04-12-31 |
Chang-Myung Lee
DFI | Director of Finance/CFO | 47 | 20-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kyung-Mok Park
BRD | Director/Board Member | 57 | 20-12-31 |
Sang-Hyeon Mo
CEO | Chief Executive Officer | 48 | 04-12-31 |
Dae-Hyeon Jeong
CEO | Chief Executive Officer | 52 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-25 | 15,800 | +6.04% | 101 270 |
| 24-06-25 | 14,900 | -1.65% | 20,661 |
| 24-06-24 | 15,150 | -0.39% | 65,861 |
| 24-06-21 | 15,210 | +6.36% | 95,314 |
| 24-06-20 | 14,300 | +2.14% | 25,774 |
End-of-day quote Korea S.E., June 25, 2024
More quotes
Bio-FD&C Co Ltd is a Korea-based company mainly engaged in the and research, development and manufacture of plant cell derived active substances and plant cell derived pharmacological substances. The Company is mainly engaged in the manufacture and sale of soybean callus culture extract, clock stem cell, centella asiatica, callus extract, aloe barbadensis phytoplaceta extract, prunus mume phytoplacenta extract, secale cereale adventitious root extract, acanthopanax koreanum adventitious root culture extract. The Company's products are mainly used as materials for cosmeceuticals, health functional foods and pharmaceuticals.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +11.90% | 93.13M | |
| +54.73% | 815B | |
| +44.25% | 654B | |
| -6.18% | 354B | |
| +21.26% | 337B | |
| +11.10% | 302B | |
| +18.45% | 247B | |
| +2.09% | 229B | |
| +13.03% | 219B | |
| +8.84% | 171B |
- Stock Market
- Equities
- A251120 Stock
